Abstract
A 10-year-old girl was diagnosed with astrocytoma grade 2. Immuno-chemo-radiotherapy (interferon, ranimustine, and radiation), second-line chemotherapy (carboplatin and etoposide, 7 cycles) and third-line chemotherapy (ifosfamide, carboplatin, and etoposide) was given to treat progressive disease. Finally, irinotecan therapy was initiated and led to dramatic clinical improvement. Irinotecan is metabolized by carboxylesterase to form an active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT) to yield its β-glucuronide. The polymorphic UGT isoenzyme, UGT1A1 has genetic variants which decrease in SN-38 glucuronidating capacity and could help predict irinotecan-associated toxicity. The patient suffered excessive toxicity with low-dose irinotecan although no functional polymorphism in UGT1A1 was identified. We suggest that irinotecan offers an effective treatment option for children with recurrent brain stem glioma and other genetic variants except UGT1A1 may be a risk factor for irinotecan-induced toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 283-286 |
| Number of pages | 4 |
| Journal | Journal of Neuro-Oncology |
| Volume | 74 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 01-09-2005 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Neurology
- Clinical Neurology
- Cancer Research
Cite this
}
Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity : Case report. / Ishikawa, Kazuhiro; Kajita, Yasukazu; Hasegawa, Yoshinori; Noda, Yukihiro; Yoshida, Jun; Nabeshima, Toshitaka.
In: Journal of Neuro-Oncology, Vol. 74, No. 3, 01.09.2005, p. 283-286.Research output: Contribution to journal › Article
TY - JOUR
T1 - Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity
T2 - Case report
AU - Ishikawa, Kazuhiro
AU - Kajita, Yasukazu
AU - Hasegawa, Yoshinori
AU - Noda, Yukihiro
AU - Yoshida, Jun
AU - Nabeshima, Toshitaka
PY - 2005/9/1
Y1 - 2005/9/1
N2 - A 10-year-old girl was diagnosed with astrocytoma grade 2. Immuno-chemo-radiotherapy (interferon, ranimustine, and radiation), second-line chemotherapy (carboplatin and etoposide, 7 cycles) and third-line chemotherapy (ifosfamide, carboplatin, and etoposide) was given to treat progressive disease. Finally, irinotecan therapy was initiated and led to dramatic clinical improvement. Irinotecan is metabolized by carboxylesterase to form an active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT) to yield its β-glucuronide. The polymorphic UGT isoenzyme, UGT1A1 has genetic variants which decrease in SN-38 glucuronidating capacity and could help predict irinotecan-associated toxicity. The patient suffered excessive toxicity with low-dose irinotecan although no functional polymorphism in UGT1A1 was identified. We suggest that irinotecan offers an effective treatment option for children with recurrent brain stem glioma and other genetic variants except UGT1A1 may be a risk factor for irinotecan-induced toxicity.
AB - A 10-year-old girl was diagnosed with astrocytoma grade 2. Immuno-chemo-radiotherapy (interferon, ranimustine, and radiation), second-line chemotherapy (carboplatin and etoposide, 7 cycles) and third-line chemotherapy (ifosfamide, carboplatin, and etoposide) was given to treat progressive disease. Finally, irinotecan therapy was initiated and led to dramatic clinical improvement. Irinotecan is metabolized by carboxylesterase to form an active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT) to yield its β-glucuronide. The polymorphic UGT isoenzyme, UGT1A1 has genetic variants which decrease in SN-38 glucuronidating capacity and could help predict irinotecan-associated toxicity. The patient suffered excessive toxicity with low-dose irinotecan although no functional polymorphism in UGT1A1 was identified. We suggest that irinotecan offers an effective treatment option for children with recurrent brain stem glioma and other genetic variants except UGT1A1 may be a risk factor for irinotecan-induced toxicity.
UR - http://www.scopus.com/inward/record.url?scp=26844486583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26844486583&partnerID=8YFLogxK
U2 - 10.1007/s11060-004-7119-4
DO - 10.1007/s11060-004-7119-4
M3 - Article
C2 - 16187025
AN - SCOPUS:26844486583
VL - 74
SP - 283
EP - 286
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
SN - 0167-594X
IS - 3
ER -